According to the research report, the global cell and gene therapy clinical trials market size is expected to touch USD 40.98 Billion by 2032, from USD 10.05 Billion in 2022, growing with a significant CAGR of 15.09% from 2023 to 2032.
The cell and gene therapy clinical trials report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global cell and gene therapy clinical trials in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global cell and gene therapy clinical trials market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global cell and gene therapy clinical trials during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/2881
Report Scope of the Cell and Gene Therapy Clinical Trials Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 11.57 Billion |
| Market Size by 2032 | USD 40.98 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 15.09% |
| Largest Market | North America |
| Fastest Growing Market | Asia-Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Phase and By Indication |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
This study covers a detailed segmentation of the global cell and gene therapy clinical trials market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global cell and gene therapy clinical trials market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- IQVIA
- ICON Plc
- Laboratory Corporation of America Holdings
- Charles River Laboratories International, Inc.
- PAREXEL International Corp.
- Syneos Health
- Medpace Holdings, Inc.
- PPD Inc.
- Novotech
- Veristat, LLC
Market Segmentation
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By Indication
- Oncology
- Cardiology
- CNS
- Musculoskeletal
- Infectious Diseases
- Dermatology
- Endocrine, Metabolic, Genetic
- Immunology & Inflammation
- Ophthalmology
- Hematology
- Gastroenterology
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global cell and gene therapy clinical trials report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global cell and gene therapy clinical trials market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cell and Gene Therapy Clinical Trials Market
5.1. COVID-19 Landscape: Cell and Gene Therapy Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cell and Gene Therapy Clinical Trials Market, By Phase
8.1. Cell and Gene Therapy Clinical Trials Market, by Phase, 2023-2032
8.1.1. Phase I
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Cell and Gene Therapy Clinical Trials Market, By Indication
9.1. Cell and Gene Therapy Clinical Trials Market, by Indication, 2023-2032
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Cardiology
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. CNS
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Musculoskeletal
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Infectious Diseases
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Dermatology
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Endocrine, Metabolic, Genetic
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Immunology & Inflammation
9.1.8.1. Market Revenue and Forecast (2020-2032)
9.1.9. Ophthalmology
9.1.9.1. Market Revenue and Forecast (2020-2032)
9.1.10. Hematology
9.1.10.1. Market Revenue and Forecast (2020-2032)
9.1.11. Gastroenterology
9.1.11.1. Market Revenue and Forecast (2020-2032)
9.1.12. Others
9.1.12.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Cell and Gene Therapy Clinical Trials Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Phase (2020-2032)
10.1.2. Market Revenue and Forecast, by Indication (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Indication (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Phase (2020-2032)
10.2.2. Market Revenue and Forecast, by Indication (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Indication (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Phase (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Indication (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Phase (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Indication (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Phase (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Indication (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Phase (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.4.2. Market Revenue and Forecast, by Indication (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Indication (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Phase (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Indication (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Phase (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Phase (2020-2032)
10.5.2. Market Revenue and Forecast, by Indication (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Phase (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Indication (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Phase (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Indication (2020-2032)
Chapter 11. Company Profiles
11.1. IQVIA
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. ICON Plc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Laboratory Corporation of America Holdings
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Charles River Laboratories International, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. PAREXEL International Corp.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Syneos Health
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Medpace Holdings, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. PPD Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novotech
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Veristat, LLC
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments